After Apple previewed the technology earlier this week, the FDA has now given the green light to the hearing aid features of ...

With its infectious disease blood test currently under review at the FDA, Inflammatix has obtained $57 million in new financing to help it gear up for its pending commercial roll out. | The Fierce ...

Cancer company Oncternal Therapeutics is folding all its clinical trials and laying off staff, turning its energy toward exploring strategic alternatives such as asset sales, a merger or acquisitio | ...

Just four months after Sanofi bet $80 million in upfront cash on Fulcrum Therapeutics’ losmapimod, the program has ended in a ...

F2G submitted its initial approval application with data from the first 100 patients enrolled in a phase 2b study of the drug in various invasive fungal infections due to different resistant fungi.

Moderna has vowed to cut annual R&D spending by $1.1 billion by 2027. The decision to shrink the budget by more than 20% follows commercial setbacks that have persuaded the biotech to take a “more ...

Vironexis Biotherapeutics has unveiled with $26 million and a clinical-trial-ready gene therapy that has already nabbed FDA fast track and rare pediatric disease tags. | Vironexis Biotherapeutics has ...

Sanofi will handle global commercialization of the therapy. The Big Pharma is paying RadioMedix and Orano Med 100 million euros upfront and committing up to 220 million euros in sales milestones for ...

After an initial defeat against the biggest barrier to mRNA flu vaccines—namely B strains of influenza—GSK has returned with a reformulated candidate that has ...

The European Organization for Research and Treatment of Cancer (EORTC), a network of 3,800 members across 50 countries, is ...

Shortly after a positive data drop for Eli Lilly’s efsitora a | Lilly revealed that its weekly insulin candidate efsitora ...

People with the Duffy null phenotype—who are primarily of African and Middle Eastern descent—have red blood cells that lack a ...